clinical trial · NCT07776132
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
Health Adult SubjectsHLX29HLX11
brief summary
This is a randomized, double-blind, parallel-controlled study to compare the PK profile of HLX29 and HLX11 and evaluate their safety, tolerability, and immunogenicity after a single intravenous dose in healthy male adult participants.
started
Nov 15, 2026
primary completion
Jan 31, 2027
completion
Mar 1, 2027
last updated
Oct 21, 2026
official title
A RANDOMIZED, DOUBLE-BLIND, INTRAVENOUS SINGLE-DOSE, PARALLEL-CONTROLLED PHASE I CLINICAL STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY, AND IMMUNOGENICITY OF PERTUZUMAB INJECTION BEFORE AND AFTER PROCESS CHANGE IN HEALTHY MALE PARTICIPANTS
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol